AVI Presents Data on Microbubble Delivery of Restenosis Drug at American Heart Association Annual Meeting.Business Editors/Health/Medical Writers BIOWIRE2K American Heart Association American Heart Association (AHA), n.pr a national voluntary health agency that has the goal of increasing public and medical awareness of cardiovascular diseases and stroke, and thereby reducing the number of associated deaths and disabilities. Annual Meeting PORTLAND, Ore.--(BUSINESS WIRE)--Nov. 6, 2003 AVI BioPharma, Inc. (Nasdaq:AVII) today announced the presentation of data from an independent preclinical study demonstrating the feasibility of treating cardiovascular restenosis using its proprietary microbubble mi·cro·bub·ble n. An extremely small bubble, usually only a few hundred micrometers in diameter, that can be uniformly suspended in a liquid such as blood. delivery technology in combination with a drug to prevent restenosis. The results of this study will be presented at the American Heart Association's annual meeting in Florida Sunday, Nov. 9. The study, titled "Site Specific Systemic Delivery of Rapamycin with Perfluorobutane Gas Microbubble Carrier Reduced Neointimal Formation in the Porcine Coronary Restenosis Model," will be presented by Nicholas N. Kipshidze, M.D., Ph.D., of the Lenox Hill Heart and Vascular Institute. In the study, the microbubbles were coated with a restenosis-inhibiting drug and injected intravenously. The drug-coated microbubbles accumulated at the sites of vascular injury, where the drug was then deposited. Study results showed that microbubble delivery was sufficient to prevent restenosis in a relevant animal model. "We believe that our proprietary microbubble carrier system represents a novel way to deliver drugs to prevent restenosis following coronary angioplasty," said Denis Denis, king of Portugal: see Diniz. R. Burger, Ph.D., AVI's CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. . "We are currently evaluating the role of microbubbles in a Phase II study with our NEUGENE(R) antisense agent, Resten-NG(R). This study is evaluating the efficacy and safety of Resten-NG delivered systemically with microbubbles, which, if successful, could make the drug available for broad application with stent placement and for multiple applications after angioplasty." About AVI BioPharma AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using two technology platforms: third-generation NEUGENE antisense drugs and cancer immunotherapy. AVI (Audio Video Interleaved) A Windows multimedia video format from Microsoft. It interleaves standard waveform audio and digital video frames (bitmaps) to provide reduced animation at 15 fps at 160x120x8 resolution. Audio is 11,025Hz, 8-bit samples. 's lead NEUGENE antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis, cancer, and polycystic kidney disease Polycystic Kidney Disease Definition Polycystic kidney disease (PKD) is one of the most common of all life-threatening human genetic disorders. . In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to target single-stranded RNA viruses, including West Nile virus West Nile virus, microorganism and the infection resulting from it, which typically produces no symptoms or a flulike condition. The virus is a flavivirus and is related to a number of viruses that cause encephalitis. , SARS coronavirus, calicivirus and hepatitis C. AVI's second technology, AVICINE(R), is a therapeutic cancer vaccine with late-stage trials planned for the treatment of pancreatic cancer. More information about AVI is available on the company's Web site at http://www.avibio.com/. "Safe Harbor" Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion